Teva's Copaxone (copolymer 1) demonstrated a 24% reduction in relapse rates over two years compared to placebo in relapse-remitting multiple sclerosis patients, according to a presentation of Phase III results in Paris last week by chief investigator Kenneth Johnson, professor and chairman of the department of neurology, University of Maryland School of Medicine.
The double-blind, placebo-controlled, randomized multicenter trial consisted of 281 patients assigned to either 20 mg of copolymer 1 by subcutaneous injection or placebo daily for two years. The primary endpoint was relapse rate, with secondary endpoints of time to first relapse, number of relapse-free patients, number of progression-free patients, time to progression and change in disability.
At baseline, patients in both arms of the study had mean relapse rates of 2.9 per year over the previous two years. The mean Kurtzke Expanded Disability Status Scale (EDSS) was 2.8 in the copolymer group and 2.4 in the placebo group. The mean ambulation index was 1.2 and 1.1 respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze